Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 13/20 | 1.00 |
| ▸ | HSPA1A | P0DMV8 | 9/20 | 1.00 |
| ▸ | HSPA8 | P11142 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | GAPDH | P04406 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 2/20 | 1.00 |
| ▸ | APBA1 | Q02410 | 2/20 | 1.00 |
| ▸ | MASP2 | O00187 | 1/20 | 1.00 |
| ▸ | JUND | P17535 | 1/20 | 1.00 |
| ▸ | TNNI3 | P19429 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13726132 | 0.83 | PTPN7 (0.71) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL2116061 | 0.82 | PTPN7 (1.00) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL13725202 | 0.82 | PTPN7 (0.68) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL13724800 | 0.82 | PTPN7 (0.69) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL14680373 | 0.81 | PTPN7 (1.00) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL14758490 | 0.81 | CDC25B (1.00) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL2804418 | 0.81 | CDC25B (1.00) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL13725690 | 0.80 | PTPN7 (0.81) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL10077001 | 0.80 | MAPT (0.80) | PTPN7HSPA1AHSPA8TDP1GAPDH | |
| SCHEMBL13726071 | 0.79 | PTPN7 (1.00) | PTPN7HSPA1AHSPA8TDP1GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PTPN7 1542/4885HSPA1A 3544/4885HSPA8 1921/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PTPN7 1542/4885HSPA1A 3544/4885HSPA8 1921/4885 |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | PTPN7 1828/4885HSPA1A 2298/4885HSPA8 2272/4885 |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | MCL1, AS3MT, MYADM | PTPN7 1828/4885HSPA1A 2298/4885HSPA8 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.